Videos

Jeffrey Freiberg, MD, PhD review of the SABATO trial on oral antibiotics for S aureus bacteremia and a comparison of mupirocin and iodine treatments for MRSA decolonization.

Jeffery Freiberg, MD, PhD review on key trials and challenges from 2024 in the fight against antibiotic resistance in complicated and uncomplictaed UTIs, including cefepime-taniborbactam and gepotidacin.

Jeff Freiberg, MD, PhD, on the rising emerging infection concerns of dengue, mpox, measles, and H5N1 influenza in clinical practice.

InflaRx CEO Niels Riedemann, MD, offers insights on his company’s monoclonal antibody, which demonstrated a nearly 24% reduction in 28 day all-cause mortality.

Emily Ricotta, PhD, MSc outlines the importance of involving affected populations and refining data collection methods to improve early decision-making during epidemics

Emily Ricotta, PhD, MSc, discusses how observational studies shape early decisions and address challenges in infectious disease outbreaks

Su H Wang, MD, FACP, MPH discusses combating vaccine misinformation, preventing outbreaks, and highlighting global health interconnectedness

Su H Wang, MD, FACP, MPH, cautions that the US withdrawal from the WHO and cuts to critical health programs may reverse progress in global health, with vulnerable populations being particularly at risk.

Professor Gordon Ramage, BSc, PhD, discusses the increasing impact of fungal biofilms, new treatment options, and the need for enhanced detection methods.

Carole Mitnick, ScD discusses the impact of the endTB trial's findings on future TB treatment options, including shorter treatment durations, lower costs, and expanded accessibility.

Carole Mitnick, ScD highlights the importance of trust in the success of the endTB trial and addresses the ongoing toxicity concerns with new shorter treatment regimens.

The association’s Executive Director Georges Benjamin, MD, offers some commentary as to why they have concerns around him as Health and Human Services Secretary.

Robert Walker, MD discussed the company's application for full licensure and the importance of vaccination.

The latest Phase 2/3 trial results show NVX-CoV2601 outperforms its predecessor, offering protection against emerging COVID-19 strains.

Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.

Sasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.

Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.

Gregory Fox, PhD outlines the trial's challenges, the impact of combining results with the TB Champ trial, and the role of collaboration in strengthening research outcomes.

This is the second in a series looking at the intersection of government and public health. In this segment, Contagion Editor-in-Chief Jason Gallagher, FCCP, FIDP, FIDSA, BCPS, discusses the WHO pullout, and the pauses on federal communication and research grants.

Alejandro Krolewiecki, MD discusses the path to regulatory approval, collaboration with global health organizations, and the role of partnerships in scaling up the new treatment for neglected tropical diseases.

GAFFI is addressing fungal diagnostic gaps by raising awareness, implementing models, and advocating for resource shifts, despite challenges in funding, infrastructure, and political support.

Alejandro Krolewiecki, MD, discussed testing a combination of albendazole and ivermectin to improve treatments for neglected tropical diseases.

Research into new antifungal treatments, including drugs in phase two and three trials, offers hope for patients who do not respond to current therapies.

Wendy Dann has MS and describes her experience with a copay assistance program that provides insurers with additional revenue, but does not go towards her deductible.

The impact of the "95-95 by 2025" campaign and successes in countries like Uzbekistan and Guatemala, where action to improve diagnostic tools has addressed fungal infection challenges.

George Thompson, MD, explains a rise in Valley fever cases in CA, with concerns about increased virulence, ICU admissions, and the impact of droughts and wildfires on fungal spread.

David W Denning, FRCP, FRCPath, FMedSci, outlines the "95-95 by 2025" initiative to diagnose and treat 95% of serious fungal infections globally by 2025, focused on improving access in underserved regions.

Sasirekha Ramani, PhD, discusses the potential of 2′FL as a treatment for norovirus and what more research could reveal.